HYTRIN
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 20m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYTRIN is an oral capsule small-molecule NDA approved in 1994 by Abbott. The specific indication and mechanism of action are not disclosed in available data, limiting characterization of its therapeutic profile.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting shrinking team and focus on transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Started Aug 1998
1,993 enrolled
Prostatic Hyperplasia
Career Relevance
HYTRIN currently shows zero linked job openings, indicating a mature, stable team with minimal hiring. Working on this product at LOE approaching stage means focusing on profitability extraction, managed decline, and preparing for post-LOE transition strategies.
Brand Manager
Worked on HYTRIN at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.